Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing

Edesa Biotech, Inc.

Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.
Six-month net loss $8.95M ($0.66/shr) vs $4.90M ($0.45/shr); raised ~$11.6M via ATM and direct investment.
Working capital $14.66M; cash and equivalents $15.89M at quarter end.
Phase 3 ARDS trial >25% randomized; approvals in Canada, Poland, Colombia; U.S. design discussions ongoing.
Phase 2b allergic contact dermatitis study 75% enrolled; completion expected Q4 2022, topline data early 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.